Mitsubishi Chemical HD to make Mitsubishi Tanabe Pharma Corporation a wholly owned subsidiary

Mitsubishi Chemical HD to make Mitsubishi Tanabe Pharma Corporation a wholly owned subsidiary

Mitsubishi Chemical Holdings (HD) announced on the 18th that it will invest up to 491.8 billion yen to make its consolidated subsidiary Mitsubishi Tanabe Pharma Corporation a wholly owned subsidiary. Currently, MCHC holds 56.39% of Mitsubishi Tanabe Pharma's shares, and will conduct a tender offer from January 19 to January 7, 2020, aiming to make Mitsubishi Tanabe Pharma its wholly owned subsidiary. At a press conference in Tokyo on January 18, MCHC President Hitoshi Ochi said, "The world is evolving greatly and healthcare is developing at a very fast pace. Mitsubishi Tanabe Pharma will also accelerate the overseas development of promising new drug candidates by using MCHC's human resources. The company will utilize the diverse resources of a comprehensive chemical manufacturer to efficiently create new businesses and enhance the earnings structure of a core healthcare company. (November 18, 2019, Tokyo, Japan; Credit: Nikkan Kogyo Shimbun / Kyodo News Images)

  • Product Code
  • ILEA000687907
  • Registered date
  • 2019/11/18 00:00:00
  • Credit
  • THE NIKKAN KOGYO SHIMBUN / Kyodo News Images
  • Media source
  • THE NIKKAN KOGYO SHIMBUN
  • Media size
  • 1556 × 1037 pixel
  • Resolution
  • 72 dpi
  • Deployment size
  • 983.92(KB)*
  • Special instruction
  • **The text may be generated by an automatic translation system**

*File size when opened in Photoshop, etc.

Similar Images & Videos
    Shionogi's new mid-term management plan briefing

    Shionogi's new mid-term management plan briefing

    On the 1st, Shionogi announced a new mid-term management plan to invest 500 billion yen in expanding overseas business and launching new businesses by FY2024. The company will also increase research and development expenses by 20% over the past five years to about 342.1 billion yen. In addition to strengthening its own sales of pharmaceuticals in Japan and overseas, the company will also invest heavily in products and services other than ethical drugs, such as vaccines.In terms of sales strategy, the company plans to strengthen its sales in the U.S. and China, and increase the ratio of overseas sales to more than 50% in FY2012 (18.5% in FY2007). President Tedairogi said, "We aim to become a drug discovery company that people from outside the company want to work with," and also indicated that the company will place importance on alliance strategies. (Photo taken on June 1, 2020, location unknown, credit: Nikkan Kogyo Shimbun / Kyodo News Images)
      KM Biologics begins development of vaccine for novel coronavirus

      KM Biologics begins development of vaccine for novel coronavirus

      KM Biologics (Kita Ward, Kumamoto City) has started to develop a vaccine for a new coronavirus infection. At a press conference held on April 25, President Nagasato said, "Our strength lies in the fact that we have skilled technicians and facilities from our days at the Research Institute for Chemotherapy and Serotherapy (KAKETSUKEN). As a member of the Meiji Group, we will do our utmost to expand this business. The new drug will be developed jointly with the National Institute of Infectious Diseases, the Institute of Medical Science of the University of Tokyo, and the National Institute of Biomedical Innovation, Health and Nutrition. The company will consider using its Kikuchi Research Center in Kikuchi City, Kumamoto Prefecture, and its Koshi Plant in Koshi City, Kumamoto Prefecture, which are capable of producing vaccines for 57 million new influenza cases. (Photo taken on May 25, 2020, location unknown, credit: Nikkan Kogyo Shimbun / Kyodo News Images)
        Press conference on the identification of existing drugs in Japan

        Press conference on the identification of existing drugs in Japan

        Photo shows Kohei Miyazono, Executive Vice President (Research) of the University of Tokyo, at a press conference. (March 18, 2020, Yasuda Auditorium, The University of Tokyo, Bunkyo-ku, Tokyo; Credit: Nikkan Kogyo Shimbun / Kyodo News Images)
          Fujifilm HD Chairman Komori emphasizes the significance of the acquisition.

          Fujifilm HD Chairman Komori emphasizes the significance of the acquisition.

          FUJIFILM Holdings Corporation (HD), which will acquire Hitachi, Ltd.'s diagnostic imaging systems such as computed tomography (CT) and magnetic resonance tomography (MRI), as well as electronic medical record (EMR) related services, held a press conference in Tokyo on April 18, and Chairman Shigetaka Komori emphasized the significance of the acquisition, saying, "The healthcare domain is a market with high growth potential. In particular, the company has positioned the "Diagnostics" business, including diagnostic imaging systems and medical IT, as its core business. Kenji Sukeno, President and CEO, said, "This acquisition is a combination of products with little overlap and highly complementary technologies. In September, the company acquired Yokogawa Medical Solutions, a maker of medical information systems. (Photo taken on December 18, 2019, credit: Nikkan Kogyo Shimbun / Kyodo News Images)
            JDI President Kikuoka at a press conference

            JDI President Kikuoka at a press conference

            Japan Display Inc. (JDI) has finalized a new fundraising framework totaling over 100 billion yen. In addition to raising 80-90 billion yen from Ichigo Asset Group, an independent investment fund, JDI will also sell some of its facilities at its Hakusan plant (Hakusan, Ishikawa Prefecture) to Apple Inc. On April 12, JDI announced that it had reached a basic agreement with Ichigo Trust to raise up to 90 billion yen from Ichigo. Minoru Kikuoka, president of JDI, explained the purpose of the framework at a press conference on January 12, saying, "We will sell assets in order to enhance our capital and at the same time minimize the impact on existing shareholders through dilution. He explained the purpose of the framework. Wistron, a major Taiwanese electronics manufacturing service (EMS) company, also intends to invest 50 million dollars (about 5.4 billion yen) in JDI. December 12, 2019, Tokyo, Japan; Credit: Nikkan Kogyo Shimbun / Kyodo News Images
              President Otsuka of Otsuka Furniture (left) and Chairman Yamada of Yamada Denki shake hands.

              President Otsuka of Otsuka Furniture (left) and Chairman Yamada of Yamada Denki shake hands.

              Yamada Electric will acquire 51.74% of Otsuka Furniture's shares for 4.374 billion yen on March 30, following a third-party allocation of new shares by Otsuka Furniture. Kumiko Otsuka, president of Otsuka Furniture, announced that she would continue to serve as president, saying, "It is the responsibility of the management team to accomplish this. He said that the gross profit margin of Otsuka Furniture's products is high, and he expects the company to become profitable if sales increase by 10%. President Otsuka expressed his enthusiasm, saying, "Now that the store shrinkage has run its course, we will increase sales at existing stores. Yamada is strengthening sales of products closely related to home appliances, such as houses, and by making Otsuka Furniture a subsidiary, it will also get furniture. December 12, 2019, photo credit: Nikkan Kogyo Shimbun / Kyodo News Images)
                Logo mark of Mitsubishi Chemical Holdings Corporation

                Logo mark of Mitsubishi Chemical Holdings Corporation

                Keywords : Mitsubishi Chemical Holdings Corporation, joint holding company, chemical company, chemical company, chemical, Mitsubishi Group, Mitsubishi Chemical Corporation, Mitsubishi Plastics, Mitsubishi Rayon, corporation, signboard, logo, logo mark = 2019 December 3, 2019, Marunouchi, Chiyoda-ku, Tokyo, Japan, Credit: Nikkan Kogyo Shimbun / Kyodo News Images
                  Logo mark of Mitsubishi Chemical Holdings Corporation

                  Logo mark of Mitsubishi Chemical Holdings Corporation

                  Keywords : Mitsubishi Chemical Holdings Corporation, joint holding company, chemical company, chemical company, chemical, Mitsubishi Group, Mitsubishi Chemical Corporation, Mitsubishi Plastics, Mitsubishi Rayon, corporation, signboard, logo, logo mark = 2019 December 3, 2019, Marunouchi, Chiyoda-ku, Tokyo, Japan, Credit: Nikkan Kogyo Shimbun / Kyodo News Images
                    Logo mark of Mitsubishi Chemical Holdings Corporation

                    Logo mark of Mitsubishi Chemical Holdings Corporation

                    Keywords : Mitsubishi Chemical Holdings Corporation, joint holding company, chemical company, chemical company, chemical, Mitsubishi Group, Mitsubishi Chemical Corporation, Mitsubishi Plastics, Mitsubishi Rayon, corporation, signboard, logo, logo mark = 2019 December 3, 2019, Marunouchi, Chiyoda-ku, Tokyo, Japan, Credit: Nikkan Kogyo Shimbun / Kyodo News Images
                      Mr. Uchida, President of Nissan Motor Co.

                      Mr. Uchida, President of Nissan Motor Co.

                      Makoto Uchida, 53, who took office as President and CEO of Nissan Motor Co. on January 1, held a press conference at the company's headquarters in Yokohama on February 2. Makoto Uchida, 53, held a press conference at the company's headquarters in Yokohama on February 2. He also spoke of Nissan's strengths as "employees and technology" and said, "Our mission is to develop these strengths. The current challenges are to restore trust in the company and rebuild its business performance. "He said, "We will steadily implement the foundation laid by the previous management team," and expressed his intention to promote structural reforms that combine fixed cost reductions through production rationalization and other measures with a growth strategy that includes the introduction of new models such as electric vehicles (EVs). (December 2, 2019, Nissan Motor Global Headquarters, Credit: Nikkan Kogyo Shimbun / Kyodo News Images)